+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients



The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients



Hepatology 36(4 Part 2): 662A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035942728

Download citation: RISBibTeXText


Related references

Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 75(7): 987-993, 2003

Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatric Nephrology 19(4): 365-368, 2004

Various initial presentations of Epstein-Barr virus infection-associated post-transplant lymphoproliferative disorder in pediatric liver transplantation recipients: Case series and literature review. Pediatric Transplantation 23(2): E13357, 2019

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clinical Transplantation 20(3): 389-393, 2006

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV) - seronegative adult liver transplant recipients. Transplant International 7(Suppl. S1): 235-237, 1994

Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transplant International 7(Suppl. 1): S235-S237, 1994

Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Microbiology and Infection 20(Suppl. 7): 109-118, 2014

Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. World Journal of Transplantation 6(4): 729-735, 2016

The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatric Transplantation 3(4): 271-281, 1999

Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study. Pediatric Transplantation 21(6):, 2017

Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrology Dialysis Transplantation 27(7): 2971-2979, 2012

Epstein Barr virus DNA copies in peripheral blood lymphocytes Results in solid organ transplant recipients with and without post-transplant lymphoproliferative disorder. Blood 96(11 Part 1): 336a, 2000

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 64(10): 1438-1442, 1997

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. American Journal of Transplantation 5(3): 566-572, 2005

Epstein-Barr virus-related post transplant lymphoproliferative disease of donor origin in two orthotopic liver transplant recipients. Hepatology 22(4 Part 2): 210A, 1995